Schizophrenia Research
Volume 93, Issue 1 , Pages 221-228, July 2007

Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study☆☆☆

  • Andrew Mogg

      Affiliations

    • Institute of Psychiatry, King's College London, Section of Old Age Psychiatry P070, De Crespigny Park, London SE5 8AF, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 20 78480547; fax: +44 20 78480632.
    • ,
  • Rick Purvis

      Affiliations

    • Institute of Psychiatry, King's College London, Section of Old Age Psychiatry P070, De Crespigny Park, London SE5 8AF, UK
    • ,
  • Savitha Eranti

      Affiliations

    • Institute of Psychiatry, King's College London, Section of Old Age Psychiatry P070, De Crespigny Park, London SE5 8AF, UK
    • ,
  • Faith Contell

      Affiliations

    • Institute of Psychiatry, King's College London, Section of Old Age Psychiatry P070, De Crespigny Park, London SE5 8AF, UK
    • ,
  • John P. Taylor

      Affiliations

    • Institute of Psychiatry, King's College London, Section of Old Age Psychiatry P070, De Crespigny Park, London SE5 8AF, UK
    • ,
  • Timothy Nicholson

      Affiliations

    • Institute of Psychiatry, King's College London, Section of Old Age Psychiatry P070, De Crespigny Park, London SE5 8AF, UK
    • ,
  • Richard G. Brown

      Affiliations

    • Institute of Psychiatry, King's College London, Department of Psychology, De Crespigny Park, London SE5 8AF, UK
    • ,
  • Declan M. McLoughlin

      Affiliations

    • Institute of Psychiatry, King's College London, Section of Old Age Psychiatry P070, De Crespigny Park, London SE5 8AF, UK

Received 6 February 2007; received in revised form 13 March 2007; accepted 17 March 2007. published online 10 May 2007.

Abstract 

Background

Negative symptoms in schizophrenia are associated with deficits in executive function and frequently prove highly resistant to neuroleptic medication. Using repetitive transcranial magnetic stimulation (rTMS) to activate the prefrontal cortex has been suggested as a treatment for negative symptoms.

Methods

We performed a double-blind randomized controlled pilot study of real versus sham rTMS for negative symptoms in schizophrenia. 17 right-handed patients with prominent negative symptoms (PANSS negative subscore ≥20) were randomized to a 10 day course of real (n=8) or sham rTMS (n=9) applied to the left dorsolateral prefrontal cortex (20 trains per day, 10 s treatment at 10 Hz, 50 s inter-train interval, 110% of motor threshold). The primary outcome measure was PANSS negative symptom score. Secondary outcomes included mood, cognitive function and side-effects. Patients were followed-up two weeks afterwards. The main effect of treatment arm was evaluated across end of treatment and two-week follow-up time points using ANCOVA.

Results

All subjects completed the treatment course. There was no significant difference between the two groups on PANSS negative symptom scores at either time point. At the end of treatment, no subjects in either group met the criterion for response (i.e. a 20% reduction in baseline PANSS negative symptom score). The real rTMS group had better delayed recall on a test of verbal learning than the sham group at 2 week follow-up.

Conclusions

Real rTMS was not found to be better than sham rTMS in alleviating negative symptoms of schizophrenia although it was associated with some improvement in aspects of cognitive function at follow-up.

Keywords: Transcranial magnetic stimulation, Schizophrenia, Negative symptoms

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Role of Funding Source: This study was supported by a 2003 Ritter independent Investigator Award from the National Alliance for research on Schizophrenia and Depression, the Guy's and St Thomas' Charitable Foundation (R01126), the NHS R&D National Coordinating Centre for Health Technology Assessment (NCCHTA) (98/11/04), and the Psychiatry Research Trust. These organisations had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The views and opinions expressed herein do not necessarily reflect those of any of these organisations.

☆☆ Contributors: DM McLoughlin designed the study and wrote the protocol. A Mogg performed the literature searches, undertook the statistical analyses and wrote the first draft of the manuscript. All authors contributed to and approved the final manuscript.

PII: S0920-9964(07)00147-8

doi:10.1016/j.schres.2007.03.016

Schizophrenia Research
Volume 93, Issue 1 , Pages 221-228, July 2007

Article Tools

* Image Usage & Resolution